Federal Council for the Prevention of Health Risks (Cofepris) highlighted Approved 1,974 sanitary productscovering new drugs, clinical trials and medical devices from March to September 2023.
As part of its biweekly treatment expansion report, the company announced that from March to September, there were Authorized 294 new drugs, 98 clinical trials and 1,582 medical devices.
“Among these actions, drugs and trials stand out, covering specialties such as endocrinology, gastroenterology, gynecology, hematology, infectious diseases, pulmonology, neurology, oncology, psychiatry, etc.,” he said.
Similarly, Authorized Healthcare Innovative Medical Devicessuch as infusion equipment, probes, implants, intraocular lenses, catheters, hearing aids, etc.
Apart from, Devices used to diagnose diseases such as HIV, HPV, mononucleosis, cholera, herpes and diabetesin addition to surgical lasers, defibrillators, ventilation-assisted resuscitators, microscopes, video laryngoscopes, surgical instruments and other medical equipment.
It noted in its latest report that in the second half of September, 30 drugs approvedwhich stands out Five innovative molecules: amlodipine/losartan/chlorthalidoneused to treat high blood pressure; dexrabeprazole, designed to treat gastroesophageal reflux disease; fampridine, used to treat multiple sclerosis; memantine, used to help fight Alzheimer’s disease; and opatadine /Mometasone, used to treat allergic rhinitis.
Similarly, nine medical trialsincluding one designed to evaluate new alternatives Treat anaplastic lymphoma, Another focuses on treatments for lupus, and another is more focused on new treatment options for breast cancer.
Regarding medical devices, authorization has been issued 49 Devices Used in Healthcare; Among them: drainage tubes, digital hearing aids and bone bioimplants.
“Forty-nine diagnostic supplies and 34 medical devices were approved, such as video gastroscopy systems, video laryngoscopes and ventilation-assisted resuscitators, for a total of 132 new authorized devices,” he said.